Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
This observational or N/A phase trial investigates Chronic Myeloid Leukemia and is currently ongoing. Gruppo Italiano Malattie EMatologiche dell'Adulto leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting
▶ Show 6 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Apr 2019 [monthly]
Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
-
Apr 2017 — Mar 2018 [monthly]
Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gruppo Italiano Malattie EMatologiche dell'Adulto
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Baghdad, Iraq , Bari, Italy , Bologna, Italy , Brescia, Italy , Cagliari, Italy , Catania, Italy , Eindhoven, Netherlands , Emory, United States , Genova, Italy and 19 more locations